AU2002357114B2 - Treatment of neoplasia - Google Patents

Treatment of neoplasia Download PDF

Info

Publication number
AU2002357114B2
AU2002357114B2 AU2002357114A AU2002357114A AU2002357114B2 AU 2002357114 B2 AU2002357114 B2 AU 2002357114B2 AU 2002357114 A AU2002357114 A AU 2002357114A AU 2002357114 A AU2002357114 A AU 2002357114A AU 2002357114 B2 AU2002357114 B2 AU 2002357114B2
Authority
AU
Australia
Prior art keywords
thc
apoptosis
cells
receptors
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002357114A
Other languages
English (en)
Other versions
AU2002357114A1 (en
Inventor
Catherine Lombard
Robert Mckallip
Mitzi Nagarkatti
Prakash Nagarkatti
Seongho Ryu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Publication of AU2002357114A1 publication Critical patent/AU2002357114A1/en
Application granted granted Critical
Publication of AU2002357114B2 publication Critical patent/AU2002357114B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002357114A 2001-12-07 2002-12-09 Treatment of neoplasia Ceased AU2002357114B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33673201P 2001-12-07 2001-12-07
US60/336,732 2001-12-07
PCT/US2002/039310 WO2003049727A1 (en) 2001-12-07 2002-12-09 Treatment of neoplasia

Publications (2)

Publication Number Publication Date
AU2002357114A1 AU2002357114A1 (en) 2003-06-23
AU2002357114B2 true AU2002357114B2 (en) 2008-07-24

Family

ID=23317407

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002357114A Ceased AU2002357114B2 (en) 2001-12-07 2002-12-09 Treatment of neoplasia

Country Status (6)

Country Link
US (1) US20040259936A1 (enExample)
EP (1) EP1461027A4 (enExample)
JP (1) JP2005516004A (enExample)
AU (1) AU2002357114B2 (enExample)
CA (1) CA2468794A1 (enExample)
WO (1) WO2003049727A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632955B2 (en) * 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
US7528165B2 (en) * 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
WO2005023232A2 (en) * 2003-09-04 2005-03-17 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
EP1736775A4 (en) * 2004-04-12 2008-03-12 Takeda Pharmaceutical NEW LIGAND OF A G-PROTEIN-COUPLED RECEPTOR PROTEIN AND USE THEREOF
TWI360539B (en) 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
MX2009005071A (es) * 2006-11-13 2009-05-25 Novartis Ag Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.
EP2470508A1 (en) 2009-08-28 2012-07-04 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CA2789151A1 (en) 2010-02-08 2011-08-11 Allergan, Inc. Pyridazine derivatives useful as cannabinoid-2 agonists
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
MX392150B (es) 2011-02-25 2025-03-21 Arena Pharm Inc Moduladores de receptores canabinoides.
JP5945554B2 (ja) 2011-02-25 2016-07-05 アリーナ ファーマシューティカルズ， インコーポレイテッド 縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター）
WO2016085941A1 (en) 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
CN114096241A (zh) * 2019-05-16 2022-02-25 技术研究及发展基金有限公司 大麻素及其用途
CN115282279B (zh) * 2022-08-08 2024-03-12 暨南大学附属第一医院（广州华侨医院） CNR2通过介导DCs成熟及功能作为脓毒症急性肺损伤治疗靶点的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057107A2 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Cannabinoids selective for the cb2 receptor
US5990170A (en) * 1994-12-14 1999-11-23 Lifegroup S.P.A. Therapeutic use of mono and bicarboxylic acid amides active at the peripheral cannabinoid receptor
WO2001029007A1 (en) * 1999-10-18 2001-04-26 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
WO2001032629A1 (fr) * 1999-11-03 2001-05-10 Sanofi-Synthelabo Derives trycycliques d'acides 1-benzylpyrazole-3-carboxylique comme antagonistes des recepteurs de cannabinoides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990170A (en) * 1994-12-14 1999-11-23 Lifegroup S.P.A. Therapeutic use of mono and bicarboxylic acid amides active at the peripheral cannabinoid receptor
WO1999057107A2 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Cannabinoids selective for the cb2 receptor
WO2001029007A1 (en) * 1999-10-18 2001-04-26 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
WO2001032629A1 (fr) * 1999-11-03 2001-05-10 Sanofi-Synthelabo Derives trycycliques d'acides 1-benzylpyrazole-3-carboxylique comme antagonistes des recepteurs de cannabinoides

Also Published As

Publication number Publication date
EP1461027A1 (en) 2004-09-29
WO2003049727A1 (en) 2003-06-19
US20040259936A1 (en) 2004-12-23
AU2002357114A1 (en) 2003-06-23
CA2468794A1 (en) 2003-06-19
EP1461027A4 (en) 2005-09-07
JP2005516004A (ja) 2005-06-02

Similar Documents

Publication Publication Date Title
McKallip et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease
Marcu et al. Cannabidiol enhances the inhibitory effects of Δ9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival
Lombard et al. CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents
US20040259936A1 (en) Treatment of neoplasia
Blázquez et al. Cannabinoid receptors as novel targets for the treatment of melanoma
TWI259077B (en) Combinations of drugs for the treatment of neoplastic disorders
ES2732005T3 (es) Una combinación de tetrahidrocannabinol y cannabidiol para uso para aumentar la radiosensibilidad en el tratamiento de un tumor cerebral
AU2009307099B2 (en) Use of tocotrienol composition for the prevention of cancer
Zhou et al. HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects
AU2009254936A1 (en) Anti-tumoural effects of cannabinoid combinations
US20100029739A1 (en) Use of a combination of hypothermia inducing drugs
US20030039628A1 (en) Activation and protection of T-cells (CD4+ and CD8+) using an H2 receptor agonist and other T-cell activating agents
US20140187495A1 (en) Methods for treating glioblastoma
EP1303265B1 (en) Use of cox-2 inhibitors as immunostimulants in the treatment of hiv or aids
CN111249272B (zh) 茶多酚在作为免疫检查点抑制剂及制备用于抗肿瘤的药物中的应用
CN103251585B (zh) 青蒿素及其衍生物在抑制血小板衍生生长因子受体a中的作用及其应用
EP2991733A1 (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
US7358245B2 (en) Treatment of gastroesophageal reflux disease
WO2009108755A2 (en) Pharmaceutical combinations for the treatment of cancer
JP5680816B2 (ja) ３，３’−ジインドリルメタン免疫活性化組成物
JP2016521689A (ja) シナラ属種の抽出物及びその使用
CN105232568B (zh) 木蝴蝶苷b的应用及含木蝴蝶苷b的药物
Helvaci et al. Smoking and sickle cell diseases
EP1656147B1 (en) Diflunisal for the treatment of cancer
Wang et al. Selective Inhibition of Natural Killer but not Natural Cytotoxic Activity in a Cloned Cell Line by Delta‐9‐Tetrahydrocannabinol

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired